Page for
testing

About Gubra

Founded in 2008, we are a privately-held biotech company with two primary areas of business: Pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs.

Our focus is the metabolic space (obesity, diabetes, NASH and diabetic complications), where we specialize in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise.

We work with some of the most interesting and loyal partners and customers from across the world within big pharma, biotech and academia. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.

Quality Assurance

At Gubra, we are committed to high quality deliverables. Through the strength of our quality systems and processes, from administration and study conduction to data management and reporting, we provide structured, professional and experienced services.

All critical processes are governed by Standard Operating Procedures that along with quality control documentation are controlled by our Quality Assurance Group. Consistent training and evaluation processes throughout the organization ensure Gubra’s dynamic and evolving Quality Assurance System.

“Gubra has succeeded in combining careful design, enlightened scientific methodology and rigorous attention to detail with timely reporting. This is a rare feat for a CRO, and one that sets Gubra apart from other organizations in this space.”

Michael Cowley
Head of Department of Physiology, Monash University